Tectonic Therapeutic (TECX) Liabilities and Shareholders Equity (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $246.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $246.6 million, down 21.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 30.06% YoY), and the FY2025 annual result was $261.0 million, up 70.72% from the prior year.
• Liabilities and Shareholders Equity fell to $246.6 million in Q1 2026 per TECX's latest filing, from $261.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $314.8 million in Q1 2025 and troughed at $39.4 million in Q4 2023.
• A 5-year average of $172.0 million and a median of $152.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 62.1% in 2023, then soared 288.09% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $103.9 million in 2022, then slumped by 62.1% to $39.4 million in 2023, then soared by 288.09% to $152.9 million in 2024, then soared by 70.72% to $261.0 million in 2025, then declined by 5.54% to $246.6 million in 2026.
• Business Quant data shows TECX's Liabilities and Shareholders Equity at $246.6 million in Q1 2026, $261.0 million in Q4 2025, and $277.0 million in Q3 2025.